

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

PROFIT ALERT — EXPECTED REDUCTION IN LOSS

This announcement is made by Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2024 (“**Year 2024**”), the Group is expected to record a net loss in the range of approximately RMB146 million to approximately RMB151 million for Year 2024, as compared to a net loss of approximately RMB189.6 million for the year ended 31 December 2023.

The Board believes that the aforementioned reduction in loss is primarily attributable to increased sales revenue resulting from enhanced market penetration, decreased sales costs due to optimized production processes, and reduced selling expenses achieved through stringent control of sales expenditures.

The Board wishes to emphasize that the information contained in this announcement is only a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Group for Year 2024. The information contained in this announcement has not been audited or reviewed by the Company’s auditor and is subject to adjustments and changes.

Details of the Group’s financial results and performance for Year 2024 will be disclosed in the Company’s annual results announcement, which is expected to be published at the end of March 2025.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 25 February 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Mr. Zhu Pai as non-executive Directors; and (iii) Dr. Meng Songdong, Ms. Qi Jingyao and Mr. Ran Dong as independent non-executive Directors.